Amber Makani, MD
Interventional Cardiology · Monroeville, PANPI 1124447479
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (52.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Abbott at 49.7% of the total.
Across 253 payments — averaging $310.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$39K
- Medtronic$33K
- Biotronik Inc.$2K
- Boston Scientific$2K
- Edwards Lifesciences$1K
- Abiomed$627
- plus $2K from 14 others
What the payments were for
- Consulting fees$14,12518%
- Speaking & faculty fees$4,7506%
- Grants$41,05052%
- Travel & lodging$8,67511%
- Food & beverage$9,40212%
- Education$680%
- Entertainment$1040%
- Other$2820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 111 | $38,965 |
| Medtronic(2 entities) | 62 | $32,528 |
| Biotronik Inc. | 7 | $1,767 |
| Boston Scientific | 19 | $1,604 |
| Edwards Lifesciences | 15 | $1,296 |
| Abiomed | 6 | $627 |
| Shockwave Medical, Inc | 3 | $347 |
| Cardiovascular Systems Inc. | 5 | $288 |
| Verge Medical, Inc. | 2 | $214 |
| Janssen Scientific Affairs, LLC | 2 | $206 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $154 |
| Opsens Inc. | 1 | $104 |
| Inari Medical, Inc. | 1 | $102 |
| W. L. Gore & Associates, Inc. | 3 | $72 |
| Asahi Intecc USA, Inc. | 5 | $49 |
| Amgen | 2 | $41 |
| Novartis | 2 | $28 |
| Heartflow, Inc. | 1 | $26 |
| Terumo Medical Corporation | 1 | $24 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NAVITOR$21,920
- MitraClip$1,825
- COREVALVE EVOLUT R$1,236
- AMPLATZER$1,023
- VersaCross Access Solution$564
- PORTICO$549
- Passeo-18$535
- Pulsar-18 T3$535
- PRO-Kinetic Energy$535
- Orsiro Mission$535
- PK Papyrus$535
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$459
- Impella$439
- WATCHMAN Access System$341
- AMPLATZER AMULET$258
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$234
- FLASH Ostial System$214
- AMPLATZER TALISMAN$153
- RESOLUTE ONYX$140
- Diamondback Coronary$120
How this compares
$78,454 in reported general payments places this provider in the 85th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 132 | $127,722 |
| EntrestoSacubitril/Valsartan | 67 | $72,639 |
| JardianceEmpagliflozin | 68 | $70,513 |
| Repatha SureclickEvolocumab | 48 | $41,389 |
| XareltoRivaroxaban | 31 | $33,633 |
| Rosuvastatin Calcium | 225 | $3,024 |
| Metoprolol Succinate | 143 | $1,809 |
| Atorvastatin Calcium | 124 | $1,572 |
| Losartan Potassium | 119 | $1,404 |
| Nifedipine ErNifedipine | 28 | $1,192 |
| Potassium Chloride | 21 | $1,186 |
| ClopidogrelClopidogrel Bisulfate | 67 | $910 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 56 | $714 |
| Metoprolol Tartrate | 75 | $664 |
| Spironolactone | 76 | $627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $28 | $72,63967 claims |
| Johnson & JohnsonXarelto | $14 | $33,63331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Monroeville
- Aashish DuaMonroeville$189K
- Nishant SethiScranton$1.3M
- Matthew BeckerErie$1M
- William GrayWynnewood$753K
- Jon GeorgePhiladelphia$637K
- Shailendra SinghAllentown$470K
- Sanjog KalraPhiladelphia$444K
- James HarveyChambersburg$442K
- Taisei KobayashiPhiladelphia$384K
- Antonis PratsosBroomall$377K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.